Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to IntelliA Therapeutics' second quarter 2025 Financial Results Conference call. My name is Drew and I will be your conference operator today. Following formal remarks, we will open the call up for a question and answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. As a reminder, all participants are currently in listen-only mode. If anyone requires operator assistance during the conference, please press star zero on your telephone keypad. I will now turn the conference over to Brittany Chavez, Senior Manager of Invest Relations at IntelliA. Please proceed. Thank you, operator, and good morning, everyone. Welcome to IntelliA Therapeutics' second quarter 2025 earnings call. Earlier this morning, IntelliA issued a press release outlining the company's progress this quarter as well as topics for discussion on today's call. This release can be found on the Investors in Media section of IntelliA's website at Intelliatx.com. This call is being broadcast live and a replay will be archived on the company's website. At this time, I would like to take a minute to remind listeners that during this call, IntelliA management may make certain forward-looking statements and ask you to refer to our SEC filings available for discussion of potential risks and uncertainties. All information presented on this call is current as of today and IntelliA undertakes no duty to update this information unless required by law. Joining me from IntelliA are John Leonard, Chief Executive Officer, David Lebwald, Chief Medical Officer, Ed Dulac, Chief Financial Officer, and Birgit Schultz, our Chief Scientific Officer, who will join for Q&A. John will begin with recent business...